PREMARE: Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer

Sponsor
Pere Planellas Giné (Other)
Overall Status
Completed
CT.gov ID
NCT03107650
Collaborator
(none)
323
1
30.9
10.4

Study Details

Study Description

Brief Summary

Elaboration of a preoperative prediction model of the quality of the mesorectum and the involvement of the circumferential margin in patients with mid-low rectal cancer who undergo laparoscopic anterior rectal resection.

In a second phase the investigators will study the utility of the prediction model in classifying patients with high risk of suboptimal quality of mesorectum and/or positive circumferential margin. Patients with high preoperative risk will undergo a transanal total mesorectal excision and patients with low risk a laparoscopic transabdominal mesorectal excision. The investigators finally will compare pathological outcomes ( quality of mesorectum and circumferential margin), survival and recurrence between the two groups.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Transanal total mesorectal excision of rectal cancer

Study Design

Study Type:
Observational
Actual Enrollment :
323 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer
Actual Study Start Date :
Jan 1, 2018
Actual Primary Completion Date :
Jul 31, 2019
Actual Study Completion Date :
Jul 31, 2020

Arms and Interventions

Arm Intervention/Treatment
High risk patients

Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed

Procedure: Transanal total mesorectal excision of rectal cancer
To perform a total mesorectal excision through a transanal approach

Low risk patients

Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed

Outcome Measures

Primary Outcome Measures

  1. Evaluation of the quality of mesorectum in the rectal specimen according to international consensus (goog quality, moderate quality and poor quality) [30 days]

    Evaluation of the quality of mesorectum as optimal or suboptimal (international consensus defines three grades of resection: Group 1: including mesorectal resection, good quality Group 2: intramesorectal resection: moderate quality Group 3: resection in the muscularis propria, poor quality). Investigators will group patients into two groups: optimal mesorectum (group 1) and suboptimal mesorectum (group 2-3).

  2. Evaluation of the circumferential margin status in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin) [30 days]

    Evaluation of the circumferential margin status (positive or negative) in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin)

Secondary Outcome Measures

  1. Recurrence [2 years]

    Rate of tumor recurrence

  2. Survival [2 years]

    Rate of survival

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients directed to laparoscopic anterior rectal resection through a transabdominal or a transanal approach.

  • Age ≥ 18 years

  • Histology of adenocarcinoma or adenoma

  • With or without neoadjuvant chemoradiotherapy

  • TNM classification: T2 or T3, any N stage or M stage

  • Intention of resection R0

Exclusion Criteria:
  • TNM classification: T1 or T4.

  • Complicated rectal cancer or emergency surgery.

  • Previous major colorectal surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Dr. Josep Trueta of Girona Girona Spain 17007

Sponsors and Collaborators

  • Pere Planellas Giné

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pere Planellas Giné, MD PhD, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
ClinicalTrials.gov Identifier:
NCT03107650
Other Study ID Numbers:
  • 0485762
First Posted:
Apr 11, 2017
Last Update Posted:
Sep 5, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2021